Acromegaly This is an OPML file. It can be used to export all the MedWorm RSS feeds on this topic into your personal RSS reader (usually you have to save this file to your own computer before clicking on an Import OPML command in your own feed reader to upload the file which will then import all the feeds) or it can be used by webmasters to integrate MedWorm feeds with their own website. This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you the latest news and research items in this category.

Pituitary gigantism treated successfully with the growth hormone receptor antagonist, pegvisomant
(Source: Internal Medicine Journal)
Source: Internal Medicine Journal - February 27, 2013 Category: Internal Medicine Authors: A. Daniel, M. d' Emden, E. Duncan Tags: Letter to the Editor Source Type: research

Roche and Chiasma announce collaboration to develop and commercialize Chiasma's Octreolin for acromegaly and neuroendocrine tumors
Basel, 18 February 2013-Roche (SIX: RO, ROG; OTCQX: RHHBY) and Chiasma (pronounced key-azma) Inc., a privately held biopharma company, announced today that they have entered into an agreement to develop and commercialize Chiasma’s proprietary... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 19, 2013 Category: Pharmaceuticals Source Type: news

Roche, Chiasma ink deal on hormone disorder treatment (Reuters, 18 February 2013)
Drugmakers Roche and Chiasma have announced plans to work together to develop and market an oral formulation of octreotide for patients with acromegaly. Full article (Source: Society for Endocrinology)
Source: Society for Endocrinology - February 19, 2013 Category: Endocrinology Source Type: news

Roche, Chiasma partner to develop, commercialise Octreolin
Roche and Chiasma have partnered to develop and commercialise Octreolin, an investigational oral regimen for acromegaly and neuroendocrine tumours. (Source: Drug Development Technology)
Source: Drug Development Technology - February 18, 2013 Category: Pharmaceuticals Source Type: news

Roche and Chiasma announce collaboration to develop and commercialize Chiasma's Octreolin(R) for acromegaly and neuroendocrine tumors
BASEL, Switzerland, NEW YORK and JERUSALEM, Feb. 18, 2013 -- (Healthcare Sales & Marketing Network) -- Roche (SIX: RO, ROG; OTCQX: RHHBY) and Chiasma (pronounced key-az-ma) Inc., a privately held biopharma company, announced today that they have entered i... Biopharmaceuticals, Endocrinology, LicensingChiasma, Roche Group, Octreolin, acromegaly (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 18, 2013 Category: Pharmaceuticals Source Type: news

Roche and Chiasma announce collaboration to develop and commercialize Chiasma's Octreolin for acromegaly and neuroendocrine tumors
Roche and Chiasma (pronounced key-azma) Inc., a privately held biopharma company, announced today that they have entered into an agreement to develop and commercialize Chiasma’s proprietary product Octreolin, initially for acromegaly and subsequently for neuroendocrine tumors. Octreolin is an investigational oral form of the peptide octreotide, a somatostatin analog that is commercially available only by injection. Octreolin is currently in a pivotal phase 3 clinical trial for acromegaly. Under the terms of the agreement, Roche received a worldwide exclusive license to Octreolin, and will assume responsibility for th...
Source: Roche Investor Update - February 18, 2013 Category: Pharmaceuticals Source Type: news

UK Acromegaly Register Annual General Meeting
We would like to invite you to the UK Acromegaly Register AGM that will take place during the SfE BES 2013 conference. The AGM will take place in Queens Suite A, Harrogate International Centre, 12:00noon-13:00 on Tuesday 19 March 2013, and will be followed by an Ipsen sponsored symposium on acromegaly from 13:00-14:00. (Source: Society for Endocrinology)
Source: Society for Endocrinology - February 11, 2013 Category: Endocrinology Source Type: news

A Comprehensive Study of Clinical, Biochemical, Radiological, Vascular, Cardiac, and Sleep Parameters in an Unselected Cohort of Patients With Acromegaly Undergoing Presurgical Somatostatin Receptor Ligand Therapy.
Conclusions:Presurgical ATG therapy lowers GH and IGF-1 concentrations, induces tumor shrinkage, and ameliorates/reverses cardiac, vascular, and sleep complications in many patients with acromegaly. However, responses vary considerably between individuals, and attainment of biochemical control cannot be assumed to equate to universal complication control. PMID: 23393175 [PubMed - as supplied by publisher] (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - February 7, 2013 Category: Endocrinology Authors: Annamalai AK, Webb A, Kandasamy N, Elkhawad M, Moir S, Khan F, Maki-Petaja K, Gayton EL, Strey CH, O'Toole S, Ariyaratnam S, Halsall DJ, Chaudhry AN, Berman L, Scoffings DJ, Antoun NM, Dutka DP, Wilkinson IB, Shneerson JM, Pickard JD, Simpson HL, Gurnell Tags: J Clin Endocrinol Metab Source Type: research

Familial Isolated Pituitary Adenomas (FIPA) and the Pituitary Adenoma Predisposition due to Mutations in the Aryl Hydrocarbon Receptor Interacting Protein (AIP) Gene.
Abstract Pituitary adenomas are one of the most frequent intracranial tumors and occur with a prevalence of approximately 1:1000 in the developed world. Pituitary adenomas have a serious disease burden, and their management involves neurosurgery, biological therapies, and radiotherapy. Early diagnosis of pituitary tumors while they are smaller may help increase cure rates. Few genetic predictors of pituitary adenoma development exist. Recent years have seen two separate, complimentary advances in inherited pituitary tumor research. The clinical condition of familial isolated pituitary adenomas (FIPA) has been descr...
Source: ENDOCR REV - January 31, 2013 Category: Endocrinology Authors: Beckers A, Aaltonen LA, Daly AF, Karhu A Tags: Endocr Rev Source Type: research

Soluble alpha-Klotho: A novel serum biomarker for the activity of growth hormone producing pituitary adenomas.
CONCLUSION: High soluble αKL serum levels were specific to GH-producing adenomas and decreased rapidly following adenoma removal. Thus, soluble αKL appears to be a new specific and sensitive biomarker reflecting disease activity in acromegaly. Similar Klotho staining patterns in controls and acromegalics suggest that the rise in serum αKL is caused by systemic actions of pituitary GH rather than due to increased expression of Klotho by the pituitary (adenoma). PMID: 23360820 [PubMed - as supplied by publisher] (Source: European Journal of Endocrinology)
Source: European Journal of Endocrinology - January 29, 2013 Category: Endocrinology Authors: Neidert MC, Sze L, Zwimpfer C, Sarnthein J, Seifert B, Frei K, Leske H, Rushing EJ, Schmid C, Bernays R Tags: Eur J Endocrinol Source Type: research

Former model with rare growth disease dies
Acromegaly is a disorder in which there is too much growth hormone in the body (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - January 17, 2013 Category: Consumer Health News Source Type: news

Teijin Pharma to Launch Ipsen?s Somatuline Subcutaneous Injection in the Treatment of Acromegaly and Pituitary Gigantism in Japan
Tokyo, Japan / Paris, France, January 17, 2013 --- Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Ipsen (Euronext: IPN; ADR: IPSEY), today announced the launch of Somatuline® 60/90/120 mg for... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 17, 2013 Category: Pharmaceuticals Source Type: news

Tanya Angus, woman who couldn't stop growing, dies at 34
Tanya Argus became an advocate for acromegaly, a disorder that causes too much growth hormone in body (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - January 16, 2013 Category: Consumer Health News Source Type: news

Genetic analysis in young patients with sporadic pituitary macroadenomas:Beside AIP don't forget MEN1 genetic analysis.
CONCLUSION: mutations in MEN1 can be of significance in young patients with sporadic isolated pituitary macroadenomas, particularly prolactinomas, and together with AIP, we suggest genetic analysis of MEN1 in such population. PMID: 23321498 [PubMed - as supplied by publisher] (Source: European Journal of Endocrinology)
Source: European Journal of Endocrinology - January 15, 2013 Category: Endocrinology Authors: Cuny T, Pertuit M, Sahnoun-Fathallah M, Daly AF, Occhi G, Odou MF, Tabarin A, Nunes ML, Delemer B, Rohmer V, Desailloud R, Kerlan V, Chabre O, Sadoul JL, Cogne M, Caron P, Cortet C, Lienhardt-Roussie A, Raingeard I, Guedj AM, Brue T, Beckers A, Weryha G, Tags: Eur J Endocrinol Source Type: research

Resistance to octreotide LAR in acromegalic patients with high SSTR2 expression: analysis of AIP expression
We present here the clinical and molecular data of two patients with acromegaly treated with octreotide LAR after non-curative surgery, and who presented different responses to therapy. Somatostatin receptor type 2 and 5 (SSTR2 and SSTR5), and aryl hydrocarbon receptor-interacting protein (AIP) expression levels were analyzed by qPCR. In both cases, high SSTR2 and low SSTR5 expression levels were detected; however, only one of the patients achieved disease control after octreotide LAR therapy. When we analyzed AIP expression levels of both cases, the patient whose disease was controlled after therapy exhibited AIP expressi...
Source: Arquivos Brasileiros de Endocrinologia e Metabologia - January 8, 2013 Category: Endocrinology Source Type: research

Genetic studies in a coexistence of acromegaly, pheochromocytoma, gastrointestinal stromal tumor (GIST) and thyroid follicular adenoma
We report on an adult woman with rare coexistence of acromegaly, pheochromocytoma (PHEO), gastrointestinal stromal tumor (GIST), intestinal polyposis, and thyroid follicular adenoma. At the age of 56, she was diagnosed with acromegaly caused by a pituitary macroadenoma, treated by transsphenoidal surgery, radiotherapy, and octreotide. During routine colonoscopy, multiple polyps were identified as tubular adenomas with high-grade dysplasia on histology. Years later, an abdominal mass of 8.0 x 6.2 cm was detected by routine ultrasound. Surgical exploration revealed an adrenal mass and another tumor adhered to the lesser gast...
Source: Arquivos Brasileiros de Endocrinologia e Metabologia - January 8, 2013 Category: Endocrinology Source Type: research

Granulation pattern, but not GSP or GHR mutation is associated with clinical characteristics in somatostatin naive patients with somatotroph adenomas.
ConclusionsAdenoma histological phenotype, not genotype, corresponds to clinical and biochemical characteristics and response to the octreotide suppression test. Sparsely granulated adenomas constitute a clinically more unfavourable subtype but are not associated with GHR mutations in our series. Ascertainment of the adenoma subtype may become an important consideration in the management of acromegaly. PMID: 23288882 [PubMed - as supplied by publisher] (Source: European Journal of Endocrinology)
Source: European Journal of Endocrinology - January 3, 2013 Category: Endocrinology Authors: Larkin SJ, Reddy RG, Karavitaki N, Cudlip S, Wass JA, Ansorge O Tags: Eur J Endocrinol Source Type: research

The Circulating Level of FABP3 Is an Indirect Biomarker of MicroRNA-1
ConclusionsAssessment of FABP3 plasma levels in human patients might be used for indirectly measuring cardiac miR-1 activity. (Source: Journal of the American College of Cardiology: Cardiovascular Interventions)
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - December 31, 2012 Category: Cardiology Source Type: research

Localized Gigantism of Foot: Macrodysrophia Lipomatosa
(Bezmjalem Vakif University, Istanbul, Turkey)(Clinical Image; p19-20) (Source: Journal of Pakistan Medical Students)
Source: Journal of Pakistan Medical Students - December 31, 2012 Category: Universities & Medical Training Authors: JPMS Source Type: research

Giant SEPs and SEP-recovery function in Unverricht-Lundborg disease.
CONCLUSIONS: The cortical processing dysfunction generating giant SEPs in EPM1A patients consistently combines with a long-lasting suppression of hyperexcitability that leads to a delayed giant SEP-R without obstructing the response to incoming stimuli. SIGNIFICANCE: The delayed SEP-R is not due to true inhibition but the suppression of aberrant hyper-synchronisation sustaining giant SEPs. A broad middle latency SEP component adds a significantly suppressive effect. This suggests that cortico-subcortical circuitries contribute to both the gigantism and the delayed SEP-R. PMID: 23276489 [PubMed - as supplied by publishe...
Source: Clinical Neurophysiology - December 28, 2012 Category: Neurology Authors: Visani E, Canafoglia L, Rossi Sebastiano D, Agazzi P, Panzica F, Scaioli V, Ciano C, Franceschetti S Tags: Clin Neurophysiol Source Type: research

Unravelling the determinants of insular body size shifts.
Abstract The island rule, a pattern of size shifts on islands, is an oft-cited but little understood phenomenon of evolutionary biology. Here, we explore the evolutionary mechanisms behind the rule in 184 mammal species, testing climatic, ecological and phylogenetic hypotheses in a robust quantitative framework. Our findings confirm the importance of species' ecological traits in determining both the strength and the direction of body size changes on islands. Although the island rule pattern appears relatively weak overall, we find strongest support for models incorporating trait, climatic and geographical factors ...
Source: Biology Letters - December 27, 2012 Category: Biology Authors: McClain CR, Durst PA, Boyer AG, Francis CD Tags: Biol Lett Source Type: research

Novel pathway for somatostatin analogs in patients with acromegaly.
Abstract Acromegaly is a chronic disease with increased morbidity and mortality, where usually multiple treatment modalities are used. The somatostatin analogs (SSAs) are the mainstay of medical therapy but, in many patients, including those with a germline mutation in the aryl hydrocarbon receptor-interacting protein (AIP) gene, disease activity cannot be controlled with these drugs. Previous data have suggested the involvement of the tumor-suppressor gene ZAC1 in the mechanism of action of SSAs, and more recent findings suggested that SSAs could regulate AIP, which in turn can stimulate ZAC1, therefore suggesting...
Source: Trends in Endocrinology and Metabolism: TEM - December 25, 2012 Category: Endocrinology Authors: Gadelha MR, Kasuki L, Korbonits M Tags: Trends Endocrinol Metab Source Type: research

Arginine vasopressin immunoreactivity is decreased in the hypothalamic suprachiasmatic nucleus of subjects with suprasellar tumors
Abstract Suprasellar tumors with compression of the optic chiasm are associated with an impaired sleep‐wake rhythm. We hypothesized that this reflects a disorder of the biological clock of the human brain, the suprachiasmatic nucleus (SCN), which is located just above the optic chiasm. In order to test this hypothesis, we investigated the expression of two key neuropeptides of the SCN, i.e. arginine vasopressin (AVP) and vasoactive intestinal peptide (VIP), as assessed by quantitative immunocytochemistry in post‐mortem hypothalamic tissue of patients with a suprasellar tumor inducing permanent visual field defects. Pos...
Source: Brain Pathology - December 20, 2012 Category: Neurology Authors: Anke J Borgers, Eric Fliers, Jacqueline E Siljee, Dick F Swaab, Eus JW Van Someren, Peter H Bisschop, Anneke Alkemade Tags: Research Article Source Type: research

Sex-specific effects of a parasite evolving in a female-biased host population
Conclusions: We show that mature male and female Daphnia represent different environments and reveal one parasite-induced symptom (host castration), which leads to increased carrying capacity for parasite proliferation in female but not male hosts. We propose that parasite induced host castration is a property of parasites that evolved as an adaptation to specifically exploit female hosts. (Source: BMC Biology - Latest articles)
Source: BMC Biology - Latest articles - December 18, 2012 Category: Biology Authors: David DuneauPepijn LuijckxLudwig RuderDieter Ebert Source Type: research

p27(Kip1) Directly Represses Sox2 during Embryonic Stem Cell Differentiation.
Abstract The mechanisms responsible for the transcriptional silencing of pluripotency genes in differentiated cells are poorly understood. We have observed that cells lacking the tumor suppressor p27 can be reprogrammed into induced pluripotent stem cells (iPSCs) in the absence of ectopic Sox2. Interestingly, cells and tissues from p27 null mice, including brain, lung, and retina, present an elevated basal expression of Sox2, suggesting that p27 contributes to the repression of Sox2. Furthermore, p27 null iPSCs fail to fully repress Sox2 upon differentiation. Mechanistically, we have found that upon differentiation...
Source: Cell Stem Cell - December 7, 2012 Category: Stem Cells Authors: Li H, Collado M, Villasante A, Matheu A, Lynch CJ, Cañamero M, Rizzoti K, Carneiro C, Martínez G, Vidal A, Lovell-Badge R, Serrano M Tags: Cell Stem Cell Source Type: research

EMA committee recommends Aspireo Somatoprim for orphan medicinal product status
Israeli biopharmaceutical company Aspireo Pharmaceuticals' acromegaly treatment, Somatoprim, has gained a positive opinion from the Committee for Orphan Medicinal Products (COMP) at the European Medicines Agency (EMA). (Source: Drug Development Technology)
Source: Drug Development Technology - November 26, 2012 Category: Pharmaceuticals Source Type: news

Transphenoidal surgery in acromegalic patients: anatomical considerations and potential pitfalls
Conclusions The sphenoid sinus of acromegalic patients resulted in being deeper, characterized by more septa and by a reduced intercarotid distance. These alterations deserve special pre- and intraoperative care, being potentially responsible for surgical difficulties. Content Type Journal ArticleCategory Clinical Article - Neurosurgical AnatomyPages 1-6DOI 10.1007/s00701-012-1527-6Authors Giorgio Carrabba, Neurosurgery, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, University of Milano, Via Francesco Sforza 35, 20122 Milano, MI, ItalyMarco Locatelli, Neurosurgery, Fondazione IRCCS Ca�...
Source: Acta Neurochirurgica - November 25, 2012 Category: Neurology Tags: Acta Neurochirurgica Source Type: research

EMA recommends orphan product status for Aspireo’s Somatoprim
The European Medicines Agency has recommended the approval of Aspireo Pharmaceutical’s Somatoprim for the treatment of acromegaly, a rare disease that results in excess growth. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - November 25, 2012 Category: Pharmaceuticals Source Type: news

Diagnostic delay is associated with psychosocial impairment in acromegaly
Abstract The aim of this study was to systematically assess health care utilisation, diagnostic delay and psychosocial impairment in patients with acromegaly in rural versus urban health care environments. 41 patients with acromegaly were questioned to time lapse of symptom onset, first seeking medical advice and time of acromegaly diagnosis. Quality of life (QoL), and psychosocial impairment (depression, daytime sleepiness, sleep disturbances, disturbances of body image) were measured by self-assessment questionnaires. Patients were grouped into living in rural health care environments (RHCE, n = ...
Source: Pituitary - November 25, 2012 Category: Endocrinology Tags: Pituitary Source Type: research

Endoscopic endonasal approach for growth hormone secreting pituitary adenomas: outcomes in 53 patients using 2010 consensus criteria for remission
We report the outcomes of the endoscopic endonasal approach (EEA) for resection of growth hormone secreting pituitary adenomas using 2010 consensus criteria. We also assess outcomes with additional medical therapy and radiosurgery (RS) for patients not achieving remission with EEA alone. A retrospective review of 53 patients who had follow up endocrinologic data at least 3 months post-surgery was performed among patients who were treated by EEA between 1998 and 2012. Data were analyzed for remission using GH and IGF-I levels based on 2010 consensus criteria. We also analyzed the outcomes using 2000 consensus crite...
Source: Pituitary - November 25, 2012 Category: Endocrinology Tags: Pituitary Source Type: research

The Metabolic Profile in Active Acromegaly is Gender-Specific.
Conclusions:The majority of metabolic features in acromegaly are gender-specific. Active acromegaly in women is strongly associated with higher visceral adiposity dysfunction, insulin resistance, and the features of MS. We suggest more accurate metabolic management in acromegalic women, especially in the postmenopausal years. PMID: 23162101 [PubMed - as supplied by publisher] (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - November 15, 2012 Category: Endocrinology Authors: Ciresi A, Amato MC, Pivonello R, Nazzari E, Grasso LF, Minuto F, Ferone D, Colao A, Giordano C Tags: J Clin Endocrinol Metab Source Type: research

QT dispersion in patients with acromegaly
This study aimed to evaluate dQT as an early predictor of ventricular tachyarrhythmia, as sudden cardiac death commonly occurs in acromegalic patients. This cross-sectional case–control study enrolled 20 patients (10 female and 10 male) with acromegaly and 20 healthy controls (11 female and 9 male) after exclusion criteria were applied. Each participant underwent 12-lead electrocardiography, including ≥3 QRS complexes, at a speed of 25 mm/s after a 15-min rest. In each participant, the QT interval (beginning of the Q wave to the end of the T wave) was corrected (QTc) for heart rate using Bazett’s formu...
Source: Endocrine - November 13, 2012 Category: Endocrinology Tags: Endocrine Source Type: research

Oxalate Nephropathy Induced by Octreotide for AcromegalyOxalate Nephropathy Induced by Octreotide for Acromegaly
This case highlights the fact that acute kidney injury in the context of antibiotics should evoke the differential diagnosis of oxalate nephropathy in susceptible patients. Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 13, 2012 Category: Consumer Health News Tags: Nephrology Journal Article Source Type: news

How surgery for pets could save human lives
Many devoted pet owners are happy to spend thousands on operations for their cats and dogs – and these procedures could help teach scientists about human diseases, tooIf he could see himself now, Harry would be horrified. Slack-mouthed, out for the count, he has got drips going into him, tubes coming out of him, wires and sensors everywhere you look. And now the final indignity: someone is taking the clippers to that rich golden fur."Poor thing," says a nurse. "He isn't half going to look weird."There's worse to come. A neurosurgeon called Patrick Kenny is about to insert two stainless steel pins into Harry's skull. To t...
Source: Guardian Unlimited Science - November 6, 2012 Category: Science Authors: Jon Henley Tags: The Guardian World news Medical research Neuroscience Features Animals Life and style Pets Source Type: news

Active acromegaly is associated with decreased hs-CRP and NT-proBNP serum levels : Insights from the Belgian registry of acromegaly.
CONCLUSIONS:Patients with active acromegaly have significantly lower values of NT-proBNP and hs-CRP compared to patients with controlled disease and even lower values of hs-CRP compared to control subjects. PMID: 23132698 [PubMed - as supplied by publisher] (Source: European Journal of Endocrinology)
Source: European Journal of Endocrinology - November 6, 2012 Category: Endocrinology Authors: Verhelst J, Velkeniers B, Maiter D, Haentjens P, T'sjoen G, Rietzschel E, Corvilain B, Abrams P, Nobels F, Abs R, Bex M Tags: Eur J Endocrinol Source Type: research

Acromegaly induced by ectopic secretion of GHRH: A review 30 years after GHRH discovery.
Abstract Ectopic acromegaly is very rare and since the discovery of growth hormone-releasing hormone (GHRH), 30 years ago, only 74 cases have been reported in the literature. Except for a recent French series of 21 cases, most of them were case reports. The present review summarizes the current knowledge on clinical presentation, diagnosis and prognosis. Tumors secreting GHRH are neuroendocrine tumors, usually well differentiated and mainly from pancreatic or bronchial origin. They are usually large and easy to localize using TDM and somatostatin receptor scintigraphy. Clinical presentation is an acromegaly of vari...
Source: Annales d'Endocrinologie - November 1, 2012 Category: Endocrinology Authors: Borson-Chazot F, Garby L, Raverot G, Claustrat F, Raverot V, Sassolas G, GTE group Tags: Ann Endocrinol (Paris) Source Type: research

Immunoreactivity Score Using an Anti-sst2A Receptor Monoclonal Antibody Strongly Predicts the Biochemical Response to Adjuvant Treatment with Somatostatin Analogs in Acromegaly.
Conclusion:Sst2A IRS with the anti-sst2A antibody UMB-1 represents a valid tool in the clinical practice to identify acromegalic patients likely to be responders to adjuvant therapy with the currently available somatostatin analogs. PMID: 23118420 [PubMed - as supplied by publisher] (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - November 1, 2012 Category: Endocrinology Authors: Gatto F, Feelders RA, van der Pas R, Kros JM, Waaijers M, Sprij-Mooij D, Neggers SJ, van der Lelij AJ, Minuto F, Lamberts SW, de Herder WW, Ferone D, Hofland LJ Tags: J Clin Endocrinol Metab Source Type: research

A novel mass spectrometry based method for determining insulin‐like growth factor 1: assessment in a cohort of subjects with newly diagnosed acromegaly
ConclusionsuHPLC‐MS/MS offers an independent method for determining/validating IGF‐1 in subjects with acromegaly. Further studies, including the establishment of age‐ and sex‐matched reference ranges and calibration to the new International IGF‐1 standard IS 02/254, are now required to allow its introduction in to routine clinical use.© 2012 Blackwell Publishing Ltd (Source: Clinical Endocrinology)
Source: Clinical Endocrinology - November 1, 2012 Category: Endocrinology Authors: Richard Kay, David J Halsall, Anand K Annamalai, Narayanan Kandasamy, Kevin Taylor, Susanna Fenwick, Alison Webb, Gwen Wark, Steve Pleasance, Mark Gurnell Tags: Original Article Source Type: research

Acromegaly revealed by 18FDG-PET/CT in a plasmocytoma patient
Content Type Journal ArticlePages 1-2DOI 10.1007/s11102-012-0438-0Authors Jean-Christophe Maiza, Department of Endocrinology and Metabolic Diseases, Groupe Hospitalier Sud-Reunion, BP-350, 97448 Saint-Pierre, FrancePatricia Zunic, Department of Hematology, Groupe Hospitalier Sud-Reunion, BP-350, 97448 Saint-Pierre, FranceCedric Revel, Department of Nuclear Medicine, Groupe Hospitalier Felix Guyon, 97405 Saint-Denis, FranceStephane Schneebeli, Department of Endocrinology and Metabolic Diseases, Groupe Hospitalier Sud-Reunion, BP-350, 97448 Saint-Pierre, France Journal PituitaryOnline ISSN 1573-7403Print ISSN 1386...
Source: Pituitary - October 19, 2012 Category: Endocrinology Tags: Pituitary Source Type: research

Long-Term-Outcome in Patients with Acromegaly: Analysis of 1344 Patients from the German Acromegaly Register.
CONCLUSION: The majority of acromegaly patients were controlled according to their IGF-1 status. Long-term outcome could be improved by exploiting medical treatment options especially in patients who are not controlled by surgery and/or radiotherapy. PMID: 23087126 [PubMed - as supplied by publisher] (Source: European Journal of Endocrinology)
Source: European Journal of Endocrinology - October 19, 2012 Category: Endocrinology Authors: Schöfl C, Franz H, Grussendorf M, Honegger J, Jaursch-Hancke C, Mayr BM, Schopohl J Tags: Eur J Endocrinol Source Type: research

Pituitary surgery: experience from a large network in Central Switzerland.
CONCLUSIONS: Transsphenoidal surgery is the primary treatment for most sellar lesions. The use of iMRI may lead to higher gross total resection rates. In Switzerland close cooperation between specialised centres is a very positive experience both to support operative case loads and to optimise patient follow-up. PMID: 23037314 [PubMed - in process] (Source: Swiss Medical Weekly)
Source: Swiss Medical Weekly - October 18, 2012 Category: Journals (General) Authors: Berkmann S, Fandino J, Müller B, Kothbauer K, Henzen C, Landolt H Tags: Swiss Med Wkly Source Type: research

Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac arrhythmias.
CONCLUSIONS: Long-term treatment with PEG reduces HR, MHR and mHR and improves rhythm abnormalities in acromegaly. PMID: 23065994 [PubMed - as supplied by publisher] (Source: European Journal of Endocrinology)
Source: European Journal of Endocrinology - October 12, 2012 Category: Endocrinology Authors: Auriemma RS, Pivonello R, De Martino MC, Cudemo G, Grasso LF, Galdiero M, Perone Y, Colao AA Tags: Eur J Endocrinol Source Type: research

Real-world comorbidities and treatment patterns of patients with acromegaly in two large US health plan databases
Abstract Acromegaly is a rare, chronic, and debilitating disease that results from excessive growth hormone production. Clinically, this disease is associated with enlargement of soft tissue, excessive skeletal growth, and increased risk of cardiovascular disease. Acromegaly is often diagnosed late, when a wide range of comorbidities may already be present. First-line therapy for acromegaly is typically surgery; but a number of highly-specific pharmacological agents have recently enabled a more aggressive medical management of acromegaly. Since surgical cure of acromegaly is low for macroadenomas, medical co...
Source: Pituitary - October 10, 2012 Category: Endocrinology Tags: Pituitary Source Type: research

Tongue reduction for macroglossia in Beckwith Wiedemann syndrome: review and application of new technique
Abstract: Beckwith Wiedemann syndrome (BWS) is a rare, congenital overgrowth disorder that is characterized by macroglossia, anterior abdominal wall defects, visceromegaly, gigantism, and neonatal hypoglycaemia. Macroglossia may contribute to anterior open bite malocclusion with prognathism, speech articulation disturbances, drooling and the perception of intellectual disability. It was the purpose of this study to review a series of BWS patients who underwent surgical reduction of the tongue by a modified technique with respect to aesthetic and functional outcomes. Seven BWS patients, age 6 months to 21 months, had a ‘s...
Source: International Journal of Oral and Maxillofacial Surgery - October 8, 2012 Category: ENT & OMF Authors: A.A.C. Heggie, N.J. Vujcich, J.E. Portnof, A.T. Morgan Tags: Cleft Lip and Palate and Craniofacial Anomalies Source Type: research

Germline mutations of aip gene in somatotropinomas resistant to somatostatin analogues.
CONCLUSIONS: AIP germline mutations show a low, but non-negligible, prevalence in non-familial acromegaly patients with tumours resistant to somatostatin analogues treatment. PMID: 23038625 [PubMed - as supplied by publisher] (Source: European Journal of Endocrinology)
Source: European Journal of Endocrinology - October 4, 2012 Category: Endocrinology Authors: Oriola J, Perales MJ, Halperin I, Mora M, Díaz-Soto G, Salinas I, Julián MT, Olaizola I, Bernabeu I, Marazuela M, Puig-Domingo M, Lucas T, Alvarez-Escolà C, Paz DM Tags: Eur J Endocrinol Source Type: research

Difficult venepuncture – it was all in the head!
ConclusionsSeemingly trivial abnormalities may prove clinically important. One presentation of acromegaly is hard‐to‐puncture skin. (Source: Transfusion Medicine)
Source: Transfusion Medicine - October 1, 2012 Category: Hematology Authors: K. G. Badami, I. Chalmers, S. Soule, D. Walkden Tags: Case Report Source Type: research

Improvement in remission rates of the first operation in acromegalic patients.
CONCLUSION: The clinical recognition of acromegaly and outcomes of single experienced surgeons in specialized centers have significantly improved over the last years. PMID: 23015345 [PubMed - in process] (Source: Turkish Neurosurgery)
Source: Turkish Neurosurgery - September 29, 2012 Category: Neurosurgery Authors: Demir O, Gedik V, Corapcioglu D, Emral R, Unlu MA, Erdogan MF, Gullu S, Uysal AR, Baskal N Tags: Turk Neurosurg Source Type: research

A single centre audit into the outcome of transsphenoidal surgery in the treatment of acromegaly
Aim: The mainstay of treatment for growth hormone (GH) producing pituitary tumours is surgical resection using a transsphenoidal approach. Method: This audit retrospectively examined the remission rate of acromegaly following primary transsphenoidal surgery at a single centre from 2004 to 2011. The same data from 1996-2003 are also presented for comparison. Remission was defined biochemically as a GH level of less than 5 mU/L in the period 6 weeks to 6 months following surgery. (Source: International Journal of Surgery)
Source: International Journal of Surgery - September 28, 2012 Category: Surgery Authors: Edward Dyson, Nigel Mendoza Tags: Abstracts from the Assocation of Surgeons in Training Conference Source Type: research

Automated 22-kD Growth Hormone-Specific Assay without Interference from Pegvisomant [Endocrinology and Metabolism]
CONCLUSIONS: The new assay fulfils recent consensus recommendations and presents a useful new tool for reliable measurement of GH. (Source: Clinical Chemistry)
Source: Clinical Chemistry - September 28, 2012 Category: Chemistry Authors: Manolopoulou, J., Alami, Y., Petersenn, S., Schopohl, J., Wu, Z., Strasburger, C. J., Bidlingmaier, M. Tags: Endocrinology and Metabolism Source Type: research

Effects of previous growth hormone excess and current medical treatment for acromegaly on cognition
Conclusion: The total patient group scored worse compared to reference populations. We found no association between previous GH excess and cognition. In addition, current medical treatment for GH excess in acromegaly was not related to memory and executive functioning. (Source: European Journal of Clinical Investigation)
Source: European Journal of Clinical Investigation - September 19, 2012 Category: Journals (General) Authors: Pauline Brummelman, Janneke Koerts, Robin P.F. Dullaart, Gerrit van den Berg, Oliver Tucha, Bruce H.R. Wolffenbuttel, André P. van Beek Source Type: research